Find Dermatology Drugs in Phase III Clinical Development

Lead Product(s): Ruxolitinib

Therapeutic Area: Dermatology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2020

Details:

The study was testing the ruxolitinib cream in adolescent and adult patients aged 12 years and above.

Lead Product(s): Baricitinib,Corticosteroid

Therapeutic Area: Dermatology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

Details:

Study met primary endpoint of at least 75% improvement of skin inflammation. Safety profile was consistent with the known safety findings of baricitinib in atopic dermatitis.

Lead Product(s): Prabotulinumtoxin A

Therapeutic Area: Dermatology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

Details:

Primary endpoint of non-Inferiority achieved with responder rates* of 65.02% for PrabotulinumtoxinA and 62.56% for OnabotulinumtoxinA at week 4.

Lead Product(s): Calcipotriol

Therapeutic Area: Dermatology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 24, 2020

Details:

Both Lipidor's AKP01 and the comparator had a statistically significantly better efficacy compared to the placebo.

Lead Product(s): Tapinarof

Therapeutic Area: Dermatology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Japan Tobacco

Deal Size: $113.0 million Upfront Cash: $60.0 million

Deal Type: Licensing Agreement January 15, 2020

Details:

A license agreement to develop, register and market tapinarof in Japan for the treatment of dermatological diseases and conditions, including psoriasis and atopic dermatitis.

Lead Product(s): Delgocitinib

Therapeutic Area: Dermatology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Japan Tobacco

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 15, 2020

Details:

Under the terms of the agreement on October 2016nbetween JT and Torii, the drugs will be sold exclusively by Torii in Japan, following itsninclusion in the National Health Insurance (NHI) price list.

Lead Product(s): EB-101

Therapeutic Area: Dermatology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

Many patients selected for registration have completed the Stanford pre-screening process, and the Company expects to treat the first patient in the VIITALTM trial in the first quarter of 2020.

Lead Product(s): Risankizumab

Therapeutic Area: Dermatology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

SKYRIZI™ (risankizumab) met both primary and all secondary endpoints in a head-to-head, open-label study versus Cosentyx® (secukinumab).

Lead Product(s): Lebrikizumab